EAEsref Cem Atbasoglu

Esref Cem Atbasoglu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Esref Cem Atbasoglu has a total of 233 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Polygenic liability to loneliness increases psychosis risk through adolescent loneliness: evidence from the EU-GEI study

    by Javier González-Peñas, Álvaro Andreu-Bernabeu, Alberto Mora, Miguel Bernardo, Gisela Mezquida, Silvia Amoretti, Julio Bobes, Pilar A. Saiz, Maria Paz García-Portilla, Julio Sanjuan, et al.

    Social isolation and loneliness are associated with schizophrenia, yet their distinct genetic contributions and developmental pathways across the psychosis spectrum remain poorly understood. Using data from the EU-GEI study (2045 patients and 2456 healthy controls), we examined whether genetic liability to loneliness and social isolation increases psychosis risk through a two-step strategy: first testing whether polygenic scores (PGS) for loneliness and four isolation-related traits (derived from UK Biobank GWAS) were associated with first-episode psychosis (FEP), schizophrenia-spectrum disorders (SSD), symptom dimensions, and retrospectively reported loneliness and social isolation during childhood and adolescence; and second testing whether these developmental experiences mediated the relationship between genetic liability and psychosis. Genetic liability to loneliness (LNL-PGS) was associated with increased psychosis risk in the combined sample and specifically with FEP, independent of schizophrenia and depression genetic risk, with stronger effects in males. In contrast, a PGS indexing frequency of family and friends’ visits (VISITS-PGS), as a proxy for objective isolation, was associated with SSD diagnosis—particularly in females—and greater negative symptom severity. At the developmental level, LNL-PGS predicted prolonged loneliness during adolescence (ages 12–16) among patients, especially males, while VISITS-PGS only predicted lower sociability in childhood in healthy controls. Mediation analyses revealed that adolescent loneliness partially mediated the association between LNL-PGS and psychosis risk, accounting for 21% of the total effect and up to 27% in males. Together, these findings support partially distinct genetic and developmental mechanisms—with sex-specific contributions—linking perceived loneliness and objective social isolation to psychosis risk, and highlighting adolescent loneliness as a potential target for early preventive interventions.

  • Experience and attitudes of general psychiatrists in Turkiye towards persons with intellectual disability/intellectual developmental disorders: a cross-sectional survey

    by Aynur Görmez, Ertuğrul Saral, Ayşe Kurtulmuş, E. Cem Atbasoğlu, Kerim M. Munir

    The global burden of psychiatric care of intellectual disabilities/intellectual developmental disorders (IDD) remains unaddressed in general. The aim of this study was to explore the knowledge and attitudes of general adult psychiatry practitioners in Turkiye. A self-administered cross-sectional survey was conducted to gather information regarding the medical and postgraduate training experiences, views, and attitudes towards IDD (n = 265). Among the respondents, 47.9% reported receiving some training on IDD in medical school, and 75.4% during residency training. Almost all respondents felt strongly that further specialty training would be beneficial. Majority of respondents indicated that they would be willing to see patients with IDD despite finding it difficult to diagnose/manage their co-occurring mental disorders. The most common mental health problem endorsed was ‘challenging behaviour’. The most prescribed psychotropic medication class was antipsychotics. The results of the study highlight need for training, normalization, and enhancement of community inclusion in IDD.


  • Open Access

    Genetic Analysis of RASD1 as a Candidate Gene for Schizophrenia

    by Ceren Damla Durmaz, Halil Gürhan Karabulut, Meram Can Saka, Ceren Sucularlı, Güvem Gümüş Akay, Cem Atbaşoğlu, Hatice Ilgın Ruhi

    Background: RASD1 encodes Dexamethasone-induced Ras-related protein 1 (Dexras1), a protein with a critical role in signal transduction in neurons. There is a strong suspicion that dysfunction of Dexras1 might contribute to the pathogenesis of neuropsychiatric diseases. Related to its functions in intracellular signaling pathways, Dexras1 has a potential role in the etiology of schizophrenia because of its close interaction with NOS1, NOS1AP, and NMDAR, which have previously been associated with schizophrenia. Aims: To investigate the association of RASD1 variants with schizophrenia in a selected cohort from Turkey. Study Design: A case-control study. Methods: We performed targeted sequencing for the two exons, single intron, and untranslated regions of RASD1 gene in 200 individuals with schizophrenia and 100 healthy controls of Turkish origin. Results: Two rare variants, RASD1 (NM_016084.5): c.722A>T and c*31G>A were identified in individuals with schizophrenia but not in any controls. The c.722A>T was found in a single individual with schizophrenia and is a missense heterozygous variant in the second exon of RASD1, which is extremely rare in GnomAD. The other variant, c*31G>A, which was found in another individual from this schizophrenia cohort, has not been reported previously. Seven previously identified common single nucleotide polymorphisms were also detected; however, they were not significantly associated with schizophrenia in this study cohort. Conclusion: Our findings suggest that rare variants ofRASD1 might be contributing to the etiopathogenesis of schizophrenia. Further studies are needed to elucidate the underlying mechanism of this association.


  • Open Access

    Huntington Hastalığı’nın Nöropsikiyatrik Yönü

    by Özlem Devrim Balaban, E. Cem Atbaşoğlu

    Huntington Hastalığı; kore ve distoni, koordinasyon bozukluğu, bilişsel performansta bozulmalar ve davranışsal sorunlar gibi farklıfenotipler ile ortaya çıkabilen, genetik olarak otozomal dominant geçiş özelliğine sahip, ilerleyici tipte bir nörodejeneratif hastalıktır. Bilişselve motor belirtilerin yanı sıra nöropsikiyatrik belirtiler de hastalığın çekirdek belirtileri arasında yer almaktadır. Huntington Hastalığı’ndanöropsikiyatrik belirtiler oldukça sık görülmekte ve hastalığın farklı dönemlerinde psikiyatrik bozuklukların görülme prevelansı %33-76 olaraktahmin edilmektedir. Nöropsikiyatrik belirtilerin görülme sıklığı hastalığın evrelerine göre farklılık gösterse de başlangıcının motor belirtilerbaşlamadan yıllar önce olabileceği de bilinmektedir. Huntington Hastalığı’nda sık görülen nöropsikiyatrik belirti ve bozukluklar depresyon,anksiyete, intihar, irritabilite, apati, obsesif-kompulsif belirtiler, perseverasyonlar, psikoz, uyku bozuklukları ve cinsel işlev bozuklukları olaraksayılabilir. Nöropsikiyatrik belirtiler aileler üzerindeki yükün en önemli nedenlerinden birini oluşturmakta, günlük işlevsellikteki azalma ilebakım kurumlarına yerleştirilme ve hastaneye yatışların en önemli öngörücüsü olarak değerlendirilmektedir. Hem sıklığı hem de sonuçlarıgöz önüne alındığında Huntington Hastalığı’ndaki nöropsikiyatrik belirtilerin tanınması ve bu belirtilere müdahale edilmesi hastalar, hastayakınları ve bakımverenleri için oldukça önemlidir. Hastalıkta görülen nöropsikiyatrik belirtilerin tedavisi ile ilgili yüksek kanıt düzeyinesahip araştırmalar olmasa da daha düşük kanıt düzeyine sahip çalışmalar, vaka bildirimleri ve uzman görüşlerine dayalı tedavi kılavuzlarıson yıllarda yazında kendine yer bulmuştur. Bu alanda dikkat edilmesi gereken başka bir konu da risk altındaki bireylerin değerlendirilmesi,genetik danışmanlık ve bu değerlendirmeler sırasında güvenli bir protokolün oluşturulmasıdır. Bu yazıda Huntington Hastalığı’nda sık görülennöropsikiyatrik bozukluklar, bu bozuklukların tedavisi ve risk altındaki bireyleri değerlendirmede dikkat edilmesi gereken durumlar güncelyazın ışığında derlenmiştir.


  • Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings

    by Eva Velthorst, Josephine Mollon, Robin M. Murray, Lieuwe de Haan, Inez Myin Germeys, David C. Glahn, Celso Arango, Els van der Ven, Marta Di Forti, Miguel Bernardo, et al.

    Important questions remain about the profile of cognitive impairment in psychotic disorders across adulthood and illness stages. The age-associated profile of familial impairments also remains unclear, as well as the effect of factors, such as symptoms, functioning, and medication. Using cross-sectional data from the EU-GEI and GROUP studies, comprising 8455 participants aged 18 to 65, we examined cognitive functioning across adulthood in patients with psychotic disorders (n = 2883), and their unaffected siblings (n = 2271), compared to controls (n = 3301). An abbreviated WAIS-III measured verbal knowledge, working memory, visuospatial processing, processing speed, and IQ. Patients showed medium to large deficits across all functions (ES range = –0.45 to –0.73, p < 0.001), while siblings showed small deficits on IQ, verbal knowledge, and working memory (ES = –0.14 to –0.33, p < 0.001). Magnitude of impairment was not associated with participant age, such that the size of impairment in older and younger patients did not significantly differ. However, first-episode patients performed worse than prodromal patients (ES range = –0.88 to –0.60, p < 0.001). Adjusting for cannabis use, symptom severity, and global functioning attenuated impairments in siblings, while deficits in patients remained statistically significant, albeit reduced by half (ES range = –0.13 to –0.38, p < 0.01). Antipsychotic medication also accounted for around half of the impairment in patients (ES range = –0.21 to –0.43, p < 0.01). Deficits in verbal knowledge, and working memory may specifically index familial, i.e., shared genetic and/or shared environmental, liability for psychotic disorders. Nevertheless, potentially modifiable illness-related factors account for a significant portion of the cognitive impairment in psychotic disorders.


  • Higher schizotypy predicts better metabolic profile in unaffected siblings of patients with schizophrenia

    by E. Cem Atbasoglu, Guvem Gumus-Akay, Sinan Guloksuz, Meram Can Saka, Alp Ucok, Koksal Alptekin, Sevim Gullu, Jim van Os

    Type 2 diabetes (T2D) is more frequent in schizophrenia (Sz) than in the general population. This association is partly accounted for by shared susceptibility genetic variants.


  • Open Access

    Cognitive Functioning in Euthymic Bipolar Patients on Monotherapy with Novel Antipsychotics or Mood Stabilizers

    by Vesile Senturk Cankorur, Hilal Demirel, Cem Atbasoglu

    Bipolar disorder is associated with cognitive dysfunction in several domains. Medication effect is a potential confounder that can only be statistically controlled in many studies. The cognitive profile in bipolar disorder during remission on maintenance antipsychotics or mood stabilizers medication has not been compared before. We compared the cognitive profile of bipolar disorder patients euthymic for 2 month or more on monotherapy with novel antipsychotics (AP) (n=16), lithium carbonate (Li) (n=25) or valproic acid (VPA; n=26). Forty-two individuals were assessed as controls. The cognitive battery included Wechsler Adult Intelligence Scale-Revised (WAIS-R) subtests, the Wechsler Memory Scale (WMS), and Wisconsin Card Sorting Test (WCST). All three patient groups compared to controls performed poorly on the working memory and verbal memory tasks (F=3.59, df=3, p=0.02 for WAIS-R Arithmetic and F=123.64, df=3, p<0.01 for WMS Logical Memory). The differences remained significant after controlling for age. Across patients, the only significant difference was between the Li and AP groups in terms of working memory. The Li group performed better (F=3.59, df=2, p=0.02) and the difference survived correction for age and clinical features. The findings of this study suggest that working memory impairment in bipolar patients on monotherapy with atypical AP, whereas verbal memory impairment might be related to bipolar disorder itself. Working memory might be a state marker, whereas verbal memory could be a trait marker of bipolar disorder. Atypical AP might have an adverse effect on cognition in bipolar disorder. These findings cannot be generalized to all bipolar patients, particularly the poor responders to monotherapy.


  • Evaluation of drug provocation test–related anxiety in patients with drug hypersensitivity

    by Şadan Soyyiğit, Ömür Aydın, İnSu Yılmaz, Seçil Kepil Özdemir, Vesile Şentürk Cankorur, Cem Atbaşoğlu, Gülfem Elif Çelik


  • Open Access

    Exploring the Role of Social Anhedonia in the Positive and Negative Dimensions of Schizotypy in a Non-Clinical Sample

    by Burcin Cihan, Meram Can Saka, Ipek Gonüllu, Erguvan Tugba Ozel Kizil, Bora Baskak, Esref Cem Atbasoglu

    The present study aimed to investigate the role of social anhedonia, defined as the lack of ability to feel pleasure from interpersonal relationship, in a multidimensional model of schizotypy and to determine the psychometric properties of the Turkish version of Chapman’s Revised Social Anhedonia Scale (SAS) in a non-clinical sample. Second-grade students of Ankara University Medical Faculty were recruited (n=266, Mage=20.28). Confirmatory factor analysis was performed to test schizotypy dimensions. The Cronbach’s alpha internal consistency value, test–retest reliability and congruent validity of SAS were calculated. The model in which social anhedonia was allowed to load on both schizotypy dimensions fit the data set better than the model in which social anhedonia was allowed to load on negative dimension alone. The internal consistency assessed with Cronbach’s alpha was .84, test–retest reliability was r=.76 and the congruent validity of SAS was r=.55. The results of current study were consistent with those of earlier studies showing that social anhedonia was related to both schizotypy dimensions. Furthermore, the psychometric properties of the Turkish Version of SAS revealed that it is a reliable and valid measurement to assess social anhedonia in a non-clinical population.